PO-1107 miR-9 as predictor of response to Radiotherapy and Cetuximab in patients with head and neck cancers. (May 2022) - Fanetti, G.; Musco, L.; Citron, F.; Segatto, I.; Micciché, F.; Turturici, I.; Lupato, V.; Matrone, F.; Giacomarra, V.; Barzan, L.; Franchin, G.; Baldassarre, G.